FLT-PET / MRI Brain Mets

NCT04244019 · tracked via the Priya Life Science Canada tracker

Sponsor

University Health Network, Toronto

Phase

Observational

Started

2020-10-01

Last updated

2026-03-05

Condition(s) studied

Brain MetastasesRadionecrosis

Study summary

Brain metastasis (BrM) develops in approximately 40% of cancer patients. Stereotactic radiosurgery (SRS) is a form of radiotherapy that delivers high-dose per fraction to individual lesions that is commonly used to treat BrM.

Radionecrosis (RN) is an adverse event that occurs in approximately 10 - 25% of patients 6 - 24 months after treatment with SRS. Tumour progression may also occur due to local failure of treatment. Radionecrosis and tumour progression share very similar clinical features including vomiting, nausea, and focal neurologic findings.

Radionecrosis and tumour progression also share overlapping imaging characteristics. Due to their similarities, physicians need to perform a surgical resection to diagnose the complication. By using a hybrid FLT-PET/MRI scan, the investigators propose that this combination scan will provide robust data with which to differentiate between radionecrosis and tumour progression without the need for surgery. The investigators plan to conduct a single center feasibility study to investigate the potential in differentiating between SRS and tumour progression in patients, including those who may have previously undergone SRS for BrM, who are suspected to have either RN or tumour progression using hybrid FLT-PET/MRI imaging.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: 1. 18 years or older 2. Previously treated with SRS for BrM 3. New intracranial lesion with clinical and radiographic findings suspicious for either RN or tumour progression 4. May be planned surgical resection of the lesion in question. The determination that the lesion is appropriate for and may require surgical resection will be made by the multi-disciplinary brain metastasis team. Surgery is preferred but not required. If a patient is planned for surgery, the date does not need to be established and the patient does not need to have consented in order to be eligible for this study, however the imaging procedure will need to occur prior to the date of surgery. 5. A negative serum pregnancy test within the two-week interval immediately prior to PET-MRI imaging for women of child-bearing age 6. Ability to provide written informed concern to participate in the study Exclusion Criteria: 1. Previous radiotherapy to the intended treatment volume 2. Active malignancy other than sarcoma 3. Inability to remain supine for at least 60 minutes 4. Pregnancy or breast feeding 5. Age \<18 years 6. Failure to provide written informed consent 7. Contraindication for MRI as per current institutional guidelines

Primary outcome measure(s)

Radionecrosis (in patients who have previously received SRS Treatment for BrM) — 24 Months
Radionecrosis will be assessed by analyzing hybrid FLT-PET/MRI images.

Trial sites (1)

Facility	City	Region	Status
University Health Network	Toronto	Ontario

More University Health Network, Toronto trials in Canada

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Recruiting

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy Active, not recruiting

CBF and NCF Changes With Brain Radiation Active, not recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Recruiting

Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial) Recruiting

Other trials for the same condition

CBF and NCF Changes With Brain Radiation Active, not recruiting

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases Recruiting

Radiosurgery With or Without Whole Brain Radiation for Multiple Metastases Active, not recruiting

Feasibility of a Cognitive Stepped Care Program for Adults With Brain Metastases Recruiting

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04244019 on ClinicalTrials.gov ↗ ← All trials in Canada